Taiho Oncology

Boundless Bio, Taiho Oncology Partner to Study CHK1 Inhibitor, Lytgobi in Solid Tumors

Boundless is exploring its CHK1 inhibitor BBI-355 in combination studies in patients with cancer driven by extrachromosomal DNA.